CD22 is a transmembrane sialoglycoprotein and a member of the immunoglobulin superfamily. Its expression is restricted to the B cell lineage and a vast majority of B cell NHLs. CD22 plays a key role in B cell development, survival, and function. Humanized anti-CD22 antibodies were developed to minimize the immunogenicity and to enhance effector interactions during their developments of diagnostic and immunotherapeutic agent. Preclinical test with anti-CD22 antibodies indicates that a single, conjugated or radiolabeled agent has shown preliminary antitumor activity in patients with recurrent and heavily pretreated NHL. Anti-CD22 antibodies were well tolerated, without dose-dependant toxicity. Anti-CD22 antibodies are currently being evaluated in combination with rituximab, and the early results suggest that the combination of the two antibodies are well tolerated and may result in better clinical activity than the single agent alone. Thus, anti-CD22 antibodies are theoretically good candidates alone and in combination with other drugs in the treatment of B cell malignancies. In this review, the physiologic function and characteristics of CD22 antigen as target molecule of guide therapy for NHL, the types of anti-CD22 antibodies in therapy of NHL and the combination use with other antibodies were summarized.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus.
Nat Rev Rheumatol
December 2024
AMPEL BioSolutions, Charlottesville, VA, USA.
Article Synopsis
- Memory B cells in systemic lupus erythematosus (SLE) show dysfunction, being less responsive to B cell receptor (BCR) signaling but still reacting to other pathways like TLR and CD40-mediated activation.
- Chronic exposure to specific autoantibodies and immune complexes may lead to a partially inactive state in these cells, allowing for continued production of harmful anti-RNP antibodies through a self-sustaining cycle of signaling.
- Current treatments that aim at depleting B cells or targeting specific B cell receptors have shown limited success, suggesting a need to focus on addressing the dysfunction in memory B cells to better manage SLE without affecting non-involved B cell subsets.
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
J Clin Oncol
December 2024
Division of Hematology, Centre Hospitalier de Versailles, Université Versailles Paris-Saclay, Le Chesnay, France.
Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.
Patients And Methods: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870).
Development and Characterization of A Novel SpyTagged Modular Nanobody as A Detection Platform for CD22-Positive Cells.
Cell J
October 2024
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. Email:
Article Synopsis
- - The study focuses on developing a targeted therapeutic agent, FITC-SpyC-SpyT-CD22Nb, combining SpyCatcher and SpyTag proteins to recognize the CD22 surface protein found in malignant B cells.
- - Researchers used specific molecular techniques to express, purify, and label the proteins, confirming successful binding to CD22+ Raji cells with flow cytometry while showing no interaction with CD22- K562 cells.
- - The results suggest that the FITC-SpyC-SpyT-CD22Nb molecule could be used for precise targeting in cancer therapies like CAR-T cell therapy and antibody-drug conjugates.
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
Blood
September 2024
Mayo Clinic, Rochester, Minnesota, United States.
Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last two decades, it is still inferior to that of the pediatric population and once in remission, the risk of relapse is still high. Furthermore, while pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with higher morbidity and mortality. Immunotherapeutic agents offer a potential opportunity to improve response and decrease relapse without increasing toxicity.
View Article and Find Full Text PDF[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
Gan To Kagaku Ryoho
July 2024
Dept. of Hematology and Oncology, University of Fukui.
Article Synopsis
- * In Japan, four ADCs are approved: gemtuzumab ozogamicin for acute myeloid leukemia, brentuximab vedotin for various types of Hodgkin's and T-cell lymphomas (showing improved progression-free survival), inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia (with higher remission rates), and polatuzumab vedotin for diffuse large B-cell lymphoma (which also improves outcomes when used with standard chemotherapy).
- * Despite their
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!